Offshore Cash of $2 Trillion Sparks Hunt for Tax-Friendly Deals - Bloomberg: "Takeovers by U.S. companies of targets in low-tax environments -- those with a corporate tax rate of below 20 percent -- have doubled in proportion to all overseas deals, according to data compiled by Goldman Sachs Group Inc. analysts. The desire for such an arrangement, known as a tax inversion, is a factor in Medtronic Inc. (MDT)’s $42.9 billion purchase of Covidien Plc (COV) and Pfizer Inc. (PFE)’s more than $100 billion effort to buy AstraZeneca Plc. (AZN)"
Tuesday, July 1, 2014
Offshore Cash of $2 Trillion, the Hunt for Tax-Friendly Deals
Follow the money --
Offshore Cash of $2 Trillion Sparks Hunt for Tax-Friendly Deals - Bloomberg: "Takeovers by U.S. companies of targets in low-tax environments -- those with a corporate tax rate of below 20 percent -- have doubled in proportion to all overseas deals, according to data compiled by Goldman Sachs Group Inc. analysts. The desire for such an arrangement, known as a tax inversion, is a factor in Medtronic Inc. (MDT)’s $42.9 billion purchase of Covidien Plc (COV) and Pfizer Inc. (PFE)’s more than $100 billion effort to buy AstraZeneca Plc. (AZN)"
Offshore Cash of $2 Trillion Sparks Hunt for Tax-Friendly Deals - Bloomberg: "Takeovers by U.S. companies of targets in low-tax environments -- those with a corporate tax rate of below 20 percent -- have doubled in proportion to all overseas deals, according to data compiled by Goldman Sachs Group Inc. analysts. The desire for such an arrangement, known as a tax inversion, is a factor in Medtronic Inc. (MDT)’s $42.9 billion purchase of Covidien Plc (COV) and Pfizer Inc. (PFE)’s more than $100 billion effort to buy AstraZeneca Plc. (AZN)"
